Rectify Pharmaceuticals Presents New Translational Data at EASL 2026 Supporting RTY-406, its Clinical Candidate for the Treatment of Primary Sclerosing Cholangitis GlobeNewswire: May 27, 2026 Read More
Go back to Press Page
